C. Viscoli
University of Genoa
5 Papers
C. Viscoli is an academic researcher from University of Genoa. The author has contributed to research in topics: Medicine & Survival rate. The author has an hindex of 5, co-authored 5 publications.
Chat about Author
Papers
Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.
Raoul Herbrecht,Johan Maertens,L. Baila,Michel Aoun,Werner J. Heinz,Robert Martino,Stefan Schwartz,Andrew J. Ullmann,L Meert,Marianne Paesmans,Oscar Marchetti,Hamdi Akan,L. Ameye,Malathi Shivaprakash,C. Viscoli +14 more
TL;DR: Caspofungin first-line therapy was effective and well tolerated in allogeneic hematopoietic SCT patients with mycologically documented IA and no patient had a drug-related serious adverse event or discontinued because of toxicity.
158
An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients
C. Viscoli,Raoul Herbrecht,Hamdi Akan,L. Baila,Anne Sonet,A Gallamini,A Giagounidis,Oscar Marchetti,Rodrigo Martino,L Meert,Marianne Paesmans,Lieveke Ameye,Malathi Shivaprakash,Andrew J. Ullmann,Johan Maertens +14 more
TL;DR: Caspofungin provided an observed response rate compatible with the null hypothesis of a true response rate of < or =35% and underlying disease-related factors had a major impact on results.
156
Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.
A. Cometta,Winfried V. Kern,R. De Bock,Marianne Paesmans,M. Vandenbergh,Françoise Crokaert,Dan Engelhard,Oscar Marchetti,Hamdi Akan,A. Skoutelis,Volkan Korten,M. Vandercam,H. Gaya,A. Padmos,Jean Klastersky,Stephen H. Zinner,M. P. Glauser,Thierry Calandra,C. Viscoli +18 more
TL;DR: This study failed to demonstrate that the empirical addition of vancomycin therapy to the treatment regimen is of benefit to persistently febrile neutropenic patients with cancer.
Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy—EORTC Infectious Diseases Group Trial XV
Winfried V. Kern,O. Marchetti,Lubos Drgona,Hamdi Akan,Mickel Aoun,Murat Akova,Robrecht de Bock,Marianne Paesmans,C. Viscoli,Thierry Calandra +9 more
TL;DR: Monotherapy with once daily oral moxifloxacin is efficacious and safe in low-risk febrile neutropenic patients identified with the help of the MASCC scoring system, discharged early, and observed as outpatients.
85
Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.
C. Viscoli,A. Cometta,Winfried V. Kern,R. De Bock,Marianne Paesmans,Françoise Crokaert,M. P. Glauser,Thierry Calandra +7 more
TL;DR: It was concluded that piperacillin-tazobactam could be considered as monotherapy for patients with high-risk febrile neutropenia.